{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-146350","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.531270+00:00","generated_at":"2026-06-25T21:24:59.460944+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Inovio Q1 net loss $79.1M ($0.36/share); CEO Kim resigns, Shea appointed; discontinues INNOVATE trial","bullets":["Net loss $79.1M ($0.36/share) vs $54.4M ($0.27) in Q1 2021; revenue $199K.","CEO J. Joseph Kim resigns; Jacqueline Shea (former COO) appointed President and CEO; Shea base salary $700K.","Phase 3 INNOVATE trial for COVID-19 vaccine discontinues; prioritize heterologous booster strategy.","VGX-3100 BLA for cervical HSIL not expected in 2023; REVEAL2 amended to biomarker-selected population.","Cash and investments $360.4M at Mar 31, 2022, down from $401.3M at Dec 31, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-146350","json":"https://secwatch.observer/filing/0001193125-22-146350.json","markdown":"https://secwatch.observer/filing/0001193125-22-146350.md","text":"https://secwatch.observer/filing/0001193125-22-146350.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000119312522146350/0001193125-22-146350-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000119312522146350/d259881d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:24:59.460944+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a3d867bf7","claim":"Jacqueline E. Shea was appointed as President and Chief Executive Officer at INOVIO PHARMACEUTICALS, INC..","evidence_excerpt":"the Board appointed Dr. Jacqueline Shea, currently the Company’s Chief Operating Officer, to serve as the Company’s President and Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1055726/000119312522146350/0001193125-22-146350-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"808f0b319c","claim":"J. Joseph Kim resigned as President, Chief Executive Officer and Director at INOVIO PHARMACEUTICALS, INC..","evidence_excerpt":"J. Joseph Kim, President and Chief Executive Officer of the Company, resigned from those positions and also resigned as a member of the Company’s Board of Directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1055726/000119312522146350/0001193125-22-146350-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President, Chief Executive Officer and Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}